ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Enrolling by invitation · Phase 3 · NCT06194799
Conditions: Alzheimer's Disease Psychosis
At a glance
- Research payments reported, 2025
- $4.3M
- U.S. investigators named
- 20
- Sites paid
- 19
- Planned or actual enrollment
- 752
About the trial
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Tested
- ACP-204 (drug)
- Dates
- Started 2024-04-23; completion 2029-05
- Results posted
- Not yet
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Acadia Pharmaceuticals Inc reported $4.3M in research payments for this study in 2025 (1,383 payments).
Products named: Acp-204
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Muhammad M. Salim, MD Pulmonology · Chandler, AZ
- Elizabeth Zarate-rowell, M.D. Psychiatry · Seal Beach, CA
- Leonardo Alonso, M.D. Psychiatry · Miami, FL
- Emelina A. Arocha, M.D. Psychiatry · Miami, FL
- Jorge Betancourt, MD Psychiatry · Mia, FL
- Angel M. Carrasco, M.D. Neurology · Miami, FL
- Kenia Castro, M.D. Psychiatry · Hialeah, FL
- Christopher A. Fayeghi, D.O. Family Medicine · Miami, FL
- Gil Fernandez-yera, M.D. General Practice · Miami, FL
- Yaneicy Gonzalez Rojas, MD Internal Medicine · Coral Gables, FL
- Emilio Mantero Atienza, MD Psychiatry · Miami Beach, FL
- Aniel Navarro Marin, M.D. Family Medicine · Miami, FL
- Lissette Selem, PHYSICIAN/MD Psychiatry · Miami Lakes, FL
- Pilar F. Trueba, MD Family Medicine · Doral, FL
- Mohamed K. Ghumra, MD Neurology · Elgin, IL
- Muhammad Afzal Khan, MD Internal Medicine · Rahway, NJ
- Napoleon B. Higgins, M.D. Psychiatry · Friendswood, TX
- David H. Hunter, M.D. Neurology · Houston, TX
- Shahbuddin Mukardamwala, MD Neurology · Houston, TX
- Salah U. Qureshi, MD Psychiatry · Friendswood, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Verus Clinical Research Corp $2.1M
- Mediclear Medical & Research Center Inc $595,178
- Future Care Solution LLC $432,013
- Reliable Clinical Research LLC $314,345
- New Life Medical Research Center Inc $180,386
- Premier Clinical Research Institute Inc $167,737
- Homestead Associates in Research Inc $163,037
- National Institute of Clinical Research $70,777
- Mediclear Medical $68,164
- Advanced Clinical Research Network Corp $62,162
- The University of Texas Health Science Center at Houston $43,028
- Wcg Clinical Inc $37,990
- Nayab Goher $36,000
- Elias Research Associates LLC $21,500
- Chandler Clinical Research Trials LLC $20,000
- Quantum Clinical of Dade County $14,700
- Floridian Neuroscience Institute Inc $11,108
- $8,724
- Global Medical Institutes Florida LLC $5,500
- Scla Management $2,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.